article thumbnail

Canada Opens Access for Psilocybin and MDMA Therapy

Cannabis Law Report

Each request is decided on a patient-by-patient basis and approval is usually only given to drugs with successful phase II or phase II clinical trials. In 2013, section C and J of Canada’s FDR statute were amended so that “restricted drugs” were inaccessible through SAP. Subsection 56(1) Exemption.

Therapy 52
article thumbnail

Press Release: Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Cannabis Law Report

(the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“ N , N -Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DMT Therapy: Coming to a Clinic Near You?

Canna Law Blog

In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer. regulators to launch a clinical program to study the use of DMT for the treatment of stroke-related dysfunction. Several months ago, Canada-based Algernon Pharmaceuticals submitted a request to U.S.

Therapy 88
article thumbnail

New Study: Demographic and policy-based differences in behaviors and attitudes towards driving after marijuana use: an analysis of the 2013–2017 Traffic Safety Culture Index

Cannabis Law Report

We analyzed annual administrations of TSCI from 2013–2017, which asked respondents about various dimensions of traffic safety, including driving after marijuana use [ 28 ]. Between 2013 and 2017, approximately 3000 TSCI surveys were completed annually. 9-tetrahydrocannabinol on driving performance: a randomized clinical trial.

Policy 59
article thumbnail

Realm of Caring Appoints Research Director to Oversee Groundbreaking Cannabis Data Registry and Medical Studies

Cannabis Law Report

plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment. The 501(c)(3) high-impact independent public charitable organization has served tens of thousands of families and healthcare professionals since its inception in 2013. About Realm of Caring. Lindsey Clarke.

Data 105
article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Over 1,500 people from around the world attended MAPS’ Psychedelic Science 2013 conference in Oakland, CA. Rick Doblin, Ph.D.,

article thumbnail

Urge Kentucky Lawmakers to Support Medical Cannabis Reform Today!

NORML

A medical cannabis bill has been filed in the Kentucky General Assembly every year since 2013. The National Center for Biotechnology Information has summarized a group of FDA approved randomized clinical trials, finding evidence for cannabis as medicine. Nearly 80 percent of Kentuckians support medical marijuana.,

Data 187